Status:
COMPLETED
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
Lead Sponsor:
Pfizer
Conditions:
Advanced Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United King...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Patients with a documented diagnosis of aRCC.
- Patients aged ≥18 years old at the index event date.
- Patient initiated on treatment with avelumab in combination with axitinib ( ≥1 dose) on or after 1st August 2019.
- Exclusion criteria
- Patients meeting any of the following criteria will not be included in the study:
- Patients who received avelumab in combination with axitinib as part of a clinical trial
- Patients initiated on avelumab in combination with axitinib less than 12 months from the end of data collection.
- Patients who are known to have opted out of participation in any research
Exclusion
Key Trial Info
Start Date :
June 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2023
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT05394493
Start Date
June 11 2021
End Date
August 30 2023
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Ltd
Sandwich, Kent, United Kingdom, CT13 9NJ